Bausch & Lomb Corp splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Vision Care at $2.9 billion, 57% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $5.1 billion, 100% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
|---|---|---|---|---|---|
| Revenue |
5,418
|
5,101
|
4,791
|
4,146
|
3,768
|
| Operating segments | |||||
| Vision Care |
3,047
+6.2%
share 56.2%
|
2,923
+6.7%
share 57.3%
|
2,739
+7.7%
share 57.2%
|
2,543
+7.3%
share 61.3%
|
2,369
share 62.9%
|
| Pharmaceuticals |
1,404
+14.0%
share 25.9%
|
1,284
+6.2%
share 25.2%
|
1,209
+44.6%
share 25.2%
|
836
+22.8%
share 20.2%
|
681
share 18.1%
|
| Surgical |
967
+10.4%
share 17.8%
|
894
+6.0%
share 17.5%
|
843
+9.9%
share 17.6%
|
767
+6.8%
share 18.5%
|
718
share 19.1%
|
| Sales mix | |||||
| Product |
5,397
+8.9%
share 99.6%
|
5,080
+6.4%
share 99.6%
|
4,774
+15.6%
share 99.6%
|
4,131
+10.3%
share 99.6%
|
3,746
share 99.4%
|
| Brandedand Other Generic Products |
46
+15.0%
share 0.8%
|
42
+5.0%
share 0.8%
|
40
+25.0%
share 0.8%
|
32
+3.2%
share 0.8%
|
31
share 0.8%
|
| Product And Service Other |
21
+10.5%
share 0.4%
|
21
+23.5%
share 0.4%
|
17
+13.3%
share 0.4%
|
15
-31.8%
share 0.4%
|
22
share 0.6%
|
| Other Revenues |
10
+25.0%
share 0.2%
|
9
+12.5%
share 0.2%
|
8
+0.0%
share 0.2%
|
8
+14.3%
share 0.2%
|
7
share 0.2%
|
| Pharmaceutical Products |
5
+25.0%
share 0.1%
|
5
+25.0%
share 0.1%
|
4
+0.0%
share 0.1%
|
4
+0.0%
share 0.1%
|
4
share 0.1%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Ophthalmic Goods (SIC 3851)
- Listed as
- BLCO (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Vaughan, Ontario, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1860742
Other Ophthalmic Goods companies
- Alcon Inc ALC
- Cooper Companies, Inc. COO
- Warby Parker Inc. WRBY
- National Vision Holdings, Inc. EYE
- Staar Surgical Co STAA
- RxSight, Inc. RXST
- Innovative Eyewear Inc LUCY
Source: SEC EDGAR filings. This is company-reported data, not investment advice.